Related Experiment Video

Updated: Jun 23, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Oral antiplatelet therapy in the secondary prevention of atherothrombotic events

Geoffrey Ling1, Bruce Ovbiagele

  • 1Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|May 26, 2009
PubMed

Insights

Atherothrombosis, a major cause of death, requires secondary prevention. Antiplatelet therapies like aspirin and clopidogrel are effective but underutilized, necessitating improved adherence for better patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Atherothrombosis is a leading global cause of mortality and significant economic burden.
  • It underlies critical conditions such as acute coronary syndrome, cerebrovascular disease, and peripheral arterial disease.
  • Secondary prevention is crucial for patients with atherothrombosis due to high risks of recurrent ischemic events.

Purpose of the Study:

  • To review the benefits and risks of antiplatelet therapy in cardiovascular disease patients.
  • To encourage greater adherence to established treatment guidelines for atherothrombosis.
  • To improve patient outcomes through optimized secondary prevention strategies.

Main Methods:

  • Review of clinical trials on antiplatelet agents for secondary prevention.
  • Analysis of current guidelines for atherothrombosis management.
  • Discussion of quality improvement initiatives impacting treatment adherence.

Main Results:

  • Antiplatelet therapies, including aspirin, extended-release dipyridamole plus aspirin, and clopidogrel, are proven beneficial for secondary prevention.
  • Despite established efficacy and safety, the utilization of these agents in atherothrombosis patients is suboptimal.
  • Quality improvement initiatives show promise in enhancing guideline awareness and implementation.

Conclusions:

  • Antiplatelet therapy is a cornerstone of secondary prevention in atherothrombosis.
  • Addressing suboptimal utilization rates is essential for maximizing therapeutic benefits.
  • Enhanced adherence to evidence-based guidelines can significantly improve patient prognosis and reduce mortality.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...